+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07405190

Phase II Study of Ivonescimab Alone or With Carboplatin and Pemetrexed Chemotherapy for Advanced Non-Small Cell Lung Cancer with Specific Genetic Changes

Led by Massachusetts General Hospital · Updated on 2026-07-15

46

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial evaluates ivonescimab, alone or combined with carboplatin and pemetrexed chemotherapy, in patients with advanced non-small cell lung cancer NSCLC that have specific genetic changes and have received prior targeted therapies. It aims to determine how well these treatments shrink tumors, control disease progression, and affect survival, while also monitoring side effects. The study is a phase II, open-label trial focused on patients with advanced NSCLC harboring actionable genomic alterations after previous standard therapies. Participants receive ivonescimab intravenously every 3 weeks for up to 24 months if given alone. For those receiving combination therapy, ivonescimab, carboplatin, and pemetrexed are given every 3 weeks for 4 cycles each cycle lasting 21 days. After these cycles, patients with stable disease or response continue ivonescimab and pemetrexed every 3 weeks for up to a total of 24 months. Treatment continues until disease progression, unacceptable side effects, withdrawal, or other stopping criteria. Throughout the study, participants undergo regular evaluations including imaging to measure tumor response and disease status according to RECIST criteria. Researchers track the objective response rate, disease control rate, time to response, duration of response, progression-free survival, overall survival, and safety outcomes including adverse events. Follow-up continues for up to two years after the last patient enrolls, allowing long-term monitoring of treatment effects and safety. The total participation may last up to about 2 years or more depending on individual treatment and follow-up.

CONDITIONS

Brief Title

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Research Team

J

Jessica J. Lin, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here